Keeping Pace with Progressive Technologies in Biopharma Development
This episode of Drug Digest will discuss where the significant bottlenecks are in the development and manufacturing of new molecules resulting from progressive technologies, such as AI and ML, and how best to approach these challenges.Register Free: https://www.pharmtech.com/pt_w/progressive-technologiesEvent Overview:The biopharma industry is at a time where progressive technologies such as artificial intelligence, machine learning, and digitalization technologies are making a significant impact on how drug discovery, development, and manufacturing are being driven. Yet the question remains as to how the industry itself is keeping up with the fast-paced innovation churning out from these advanced technologies. This episode of Drug Digest will examine where the significant bottlenecks are in the development and manufacturing of new molecules resulting from these progressive technologies, and how best to approach these challenges.Key Learning Objectives:Where current focus is by industry participant in terms of clinical developmentIdentify key bottlenecks in the drug discovery process, development phases, and manufacturingA possible preview of some of the most promising modalities for future developmentWhat the impact will be on the biomanufacturing sector, in particularWho Should Attend:CROsCDMOs/CMOsStartup biotechs/emerging biotechsAnalytical instrument providersSpeakers:Kevin DondarskiPrincipal, Life Sciences R&DDeloitte ConsultingKevin Dondarski is a principal within Deloitte Consulting’s Life Sciences R&D practice. He has more than 20 years of experience advising clients on R&D strategy, R&D productivity, and portfolio management/capital allocation. He holds a Bachelor of Science and Master of Science in biochemical engineering from Rutgers University, and a Master of Business Administration in finance and managerial economics from the Kellogg School of Management at Northwestern University.Maryland Franklin, PhDVice-President and Enterprise Head, Cell and Gene TherapyLabcorpMaryland Franklin is vice-president and enterprise head of Cell and Gene Therapy at Labcorp, leading strategy and development. She joined Labcorp in 2019 through an acquisition, having led a preclinical oncology contract research organization team driving scientific and business success. Prior to this, with 12 years in biopharma, she helped advance multiple therapeutics, including four into Phase I trials.Franklin holds a PhD in medical genetics from the University of Alabama at Birmingham where she focused on cancer gene therapy research.Lidia Serina, PhDHead of Development ServicesSimtra BioPharma SolutionsLidia Serina, PhD, is head of Development Services at Simtra BioPharma Solutions, leading a strategic area essential to the company’s mission. She partners with clients to develop high-quality injectable products and efficient manufacturing processes. With extensive experience in supply chain, vaccine R&D, quality and regulatory compliance, and both commercial and clinical manufacturing, Serina’s technical expertise spans a wide range of molecule types. Her leadership drives innovative solutions to the complex challenges of product development and manufacturing.Sean Tucker, PhDFounder and Chief Scientific OfficerVaxartSean Tucker, PhD, is the founder of Vaxart and has served as its chief scientific officer since February 2010. From March 2004 to February 2010, Tucker served as vice-president of Research and director of Immunology. He has held numerous scientific and engineering roles at various biotechnology companies. Tucker has a Bachelor of Science in chemical engineering from the University of Washington, a Master of Science in chemical engineering from the University of California, Berkeley, and a PhD in immunology from the University of Washington.Register Free: https://www.pharmtech.com/pt_w/progressive-technologies
Details